医药导报2012，Vol.31Issue(1)：38-40,3.DOI:10.3870/yydb.2012.01.014
拉西地平对高血压并发冠心病患者血浆同型半胱氨酸水平的影响
Effect of Lacidipine on Serum Homocysteine Level of Patients with Hypertention Complicated with Coronary Heart Disease
摘要
Abstract
Objective To investigate the effect of lacidipine on serum homocysteine level of patients with hypertention and coronary heart disease. Methods One hundred eighty-four eligible patients were randomly divided into treatment group ( 93 patients ) and control group( 91 patients ). The patients in the treatment group were given with lacidipine 4 mg once a day and those in the control were treated with nifedpineines 10 mg twice a day. The duration of therapy was 3- month. The blood pressure and serum homocysteine level pre- and post-treatment were measured. Results The serum Hey level of treatment group was ( 17. 3±5. 1 ) μmol · L-1 before treatment, and the control group was ( 16. 9±4. 8 ) μmol · L-1 ;the three months later, which in the treatment group was ( 12. 5±4. 2 ) μmol · L-1 , in the control group was ( 14. 6±4. 4 ) μmol · L-1 , and the difference was remarkable( P<0. 01 ). Lacidipine was better in decreasing the Hey level than nifedpineines( P<0. 01 ). Conclusion Comparing with other calcium antagonists, the effect of lacidipine on reduction serum homocysteine level in hypertensive patient with coronary heart disease is much better and is independent of hypertension-lowering, which may be one of the unique mechanisms of its anti-arteriosclerosis.关键词
拉西地平/同型半胱氨酸/动脉粥样硬化/高血压Key words
Lacidipine/Homocysteine/Arteriosclerosis/Hypertension分类
医药卫生引用本文复制引用
王平..拉西地平对高血压并发冠心病患者血浆同型半胱氨酸水平的影响[J].医药导报,2012,31(1):38-40,3.基金项目
绍兴市科学技术局重点科技项目基金资助(2007A23009) （2007A23009）
